Enzo Biochem Inc (NYSE:ENZ): Institutional Investors Are Worried

Sentiment for Enzo Biochem Inc (NYSE:ENZ)

Enzo Biochem Inc (NYSE:ENZ) institutional sentiment decreased to 0.65 in 2018 Q4. Its down -0.61, from 1.26 in 2018Q3. The ratio worsened, as 28 investment professionals increased and opened new equity positions, while 43 reduced and sold their positions in Enzo Biochem Inc. The investment professionals in our partner’s database reported: 26.91 million shares, up from 26.61 million shares in 2018Q3. Also, the number of investment professionals holding Enzo Biochem Inc in their top 10 equity positions increased from 1 to 2 for an increase of 1. Sold All: 15 Reduced: 28 Increased: 16 New Position: 12.

Enzo Biochem, Inc., an integrated diagnostic bioscience company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company has market cap of $119.99 million. The firm operates in three divisions: Clinical Labs, Life Sciences, and Therapeutics. It currently has negative earnings. The Clinical Labs segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication levels, and search for an otherwise undiagnosed condition.

The stock decreased 4.51% or $0.12 during the last trading session, reaching $2.54. About 488,264 shares traded or 140.85% up from the average. Enzo Biochem, Inc. (NYSE:ENZ) has declined 49.77% since March 17, 2018 and is downtrending. It has underperformed by 54.14% the S&P500.

Roumell Asset Management Llc holds 6.35% of its portfolio in Enzo Biochem, Inc. for 1.11 million shares. Harbert Fund Advisors Inc. owns 1.61 million shares or 4.55% of their US portfolio. Moreover, Marathon Capital Management has 0.46% invested in the company for 332,046 shares. The Texas-based Kempner Capital Management Inc. has invested 0.18% in the stock. Cutter & Co Brokerage Inc., a Missouri-based fund reported 15,827 shares.

Since January 1, 0001, it had 3 insider purchases, and 0 insider sales for $121,256 activity.

More notable recent Enzo Biochem, Inc. (NYSE:ENZ) news were published by: Benzinga.com which released: “Earnings Scheduled For March 11, 2019 – Benzinga” on March 11, 2019, also Benzinga.com with their article: “Benzinga’s Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos – Benzinga” published on June 29, 2018, Benzinga.com published: “Benzinga’s Daily Biotech Pulse: Celgene’s Lymphoma Trial Meets Endpoint, Merit Medical’s Strong Q2, Bluebird Bio Offering – Benzinga” on July 24, 2018. More interesting news about Enzo Biochem, Inc. (NYSE:ENZ) were released by: Businesswire.com and their article: “Enzo Biochem Reports Third Quarter Results – Business Wire” published on June 11, 2018 as well as Businesswire.com‘s news article titled: “Enzo Biochem to Acquire New Facility for Manufacturing and Distribution to Advance Its Diagnostic and Therapeutic Growth Strategy – Business Wire” with publication date: August 27, 2018.

Enzo Biochem, Inc. (NYSE:ENZ) Institutional Positions Chart

(adsbygoogle = window.adsbygoogle || []).push({});

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.